APA (7th ed.) Citation

Crowley, J. J., Langley, R. G., Gordon, K. B., Pinter, A., Ferris, L. K., Rubant, S., . . . Warren, R. B. (2022). Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology & Therapy, 12(2), 561. https://doi.org/10.1007/s13555-021-00679-6

Chicago Style (17th ed.) Citation

Crowley, Jeffrey J., et al. "Efficacy of Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study." Dermatology & Therapy 12, no. 2 (2022): 561. https://doi.org/10.1007/s13555-021-00679-6.

MLA (9th ed.) Citation

Crowley, Jeffrey J., et al. "Efficacy of Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study." Dermatology & Therapy, vol. 12, no. 2, 2022, p. 561, https://doi.org/10.1007/s13555-021-00679-6.